Joint Formulary & PAD

Lacosamide - Epilepsy

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Oral solution
  • Tablets
Associated Icons :
Restrictions / Comments :
 

Status 2

Red
Formulations :
  • Infusion
Associated Icons :
Restrictions / Comments :

PAD Profile

ChemicalSubstance :
Lacosamide
Indication :
Epilepsy
Group Name :
Keywords :
Brand Names Include :
Vimpat, Eplaid
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
4
Traffic Light Entries :
2

Other Indications

Below are listed other indications that Lacosamide is used to treat.

  • No records returned.

Committee Recommendations (1)

The PCN supported the principles of switching from brand to generic medications (not recommended in the elderly) as per national guidelines in September 2013 and the proposed place in therapy of the anti-epileptic drugs which is based on NICE guidance was also discussed at that time. Transfer of care documents will be considered at a future PCN.

Please note the MHRA categorisations for each drug in the attached guidance (updated January 2014) and in the link below